GlassScriptPhysician profile
James Alford
NPI 1790751998
$767.80
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $171 · 2020: $109 · 2021: $87.32 · 2022: $29.39 · 2023: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $260 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $260.39 |
| Education | $111.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $170.98 | 2019-2023 | Liletta, Orilissa |
| Astellas Pharma US INC | $134.20 | 2023 | Veozah |
| Pfizer INC. | $118.59 | 2019-2023 | |
| Baxter Healthcare | $85.64 | 2019-2021 | |
| Exeltis, USA INC. | $74.45 | 2020-2023 | Slynd |
| Mayne Pharma Commercial LLC | $69.48 | 2023 | |
| Organon LLC | $18.23 | 2023 | Nexplanon |
| Conmed Corporation | $15.91 | 2020 | |
| Agile Therapeutics, INC. | $14.73 | 2021 | |
| Roche Diagnostics Corporation | $14.23 | 2019 | |
| Hologic Sales and Service, LLC | $13.74 | 2019 | |
| Medtronic, INC. | $13.44 | 2023 | Interstim |
| Olympus America INC. | $12.84 | 2019 | |
| Merck Sharp & Dohme LLC | $11.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Alford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.